CXCL9 and macrophage activation syndrome: Both genetic deficiency of CXCL9 in TLR9-induced MAS and FHL models as well as pharmacological inhibition of the receptor CXCR3 using AMG487 in FHL model did not ameliorate disease phenotype significantly.